A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction.

Zheng Z, Lei C, Liu H, Jiang M, Zhou Z, Zhao Y, Yu CY, Wei H

Advanced healthcare materials27 Jul 2022Cited by 98 (Europe PMC)

PMID35848825DOI10.1002/adhm.202200990PepBankPUB-35848825

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In a rat model of myocardial infarction, a liposomal composite hydrogel containing SS‑31 and S1P improved cardiac function.
In plain wordsIn rats with heart attack, a hydrogel carrying SS‑31 and another agent improved heart function.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseCardiac function
Study
ratn: not reported in source
rat myocardial infarction model
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis.
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, the liposomes contain both elamipretide (SS-31) and sphingosine-1-phosphate (S1P), where SS-31 acts as an inhibitor of mitochondrial oxidative damage and S1P as a signaling molecule for activating angiogenesis.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3584882501
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism
In a rat myocardial infarction model, the SS‑31 and S1P liposomal hydrogel scavenged excess reactive oxygen species.
In plain wordsIn rats with heart attack, a hydrogel carrying SS‑31 and another agent removed excess reactive oxygen species.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseExcess reactive oxygen species
Study
ratn: not reported in source
rat myocardial infarction model
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis.
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, the liposomes contain both elamipretide (SS-31) and sphingosine-1-phosphate (S1P), where SS-31 acts as an inhibitor of mitochondrial oxidative damage and S1P as a signaling molecule for activating angiogenesis.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3584882502
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism
In a rat myocardial infarction model, the SS‑31 and S1P liposomal hydrogel improved mitochondrial dysfunction.
In plain wordsIn rats with heart attack, a hydrogel carrying SS‑31 and another agent improved mitochondrial function.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial dysfunction
Study
ratn: not reported in source
rat myocardial infarction model
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis.
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, the liposomes contain both elamipretide (SS-31) and sphingosine-1-phosphate (S1P), where SS-31 acts as an inhibitor of mitochondrial oxidative damage and S1P as a signaling molecule for activating angiogenesis.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3584882503
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism
In a rat myocardial infarction model, the SS‑31 and S1P liposomal hydrogel promoted angiogenesis.
In plain wordsIn rats with heart attack, a hydrogel carrying SS‑31 and another agent promoted new blood vessel growth.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseAngiogenesis
Study
ratn: not reported in source
rat myocardial infarction model
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
In a rat MI model, the resulting liposomal composite hydrogel improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis.
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, the liposomes contain both elamipretide (SS-31) and sphingosine-1-phosphate (S1P), where SS-31 acts as an inhibitor of mitochondrial oxidative damage and S1P as a signaling molecule for activating angiogenesis.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3584882504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.